CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $213,332 | -14.7% | 3,800 | -0.8% | 0.01% | -26.7% |
| Q3 2022 | $250,000 | +5.9% | 3,830 | -1.6% | 0.02% | +7.1% |
| Q2 2022 | $236,000 | -0.8% | 3,891 | +2.7% | 0.01% | +27.3% |
| Q1 2022 | $238,000 | -15.3% | 3,787 | +2.3% | 0.01% | -15.4% |
| Q4 2021 | $281,000 | -14.1% | 3,702 | +26.6% | 0.01% | -23.5% |
| Q3 2021 | $327,000 | -18.5% | 2,925 | +18.2% | 0.02% | -19.0% |
| Q2 2021 | $401,000 | +33.2% | 2,474 | +0.3% | 0.02% | +16.7% |
| Q1 2021 | $301,000 | -22.0% | 2,467 | -2.2% | 0.02% | -25.0% |
| Q4 2020 | $386,000 | +83.8% | 2,522 | +0.6% | 0.02% | +60.0% |
| Q3 2020 | $210,000 | – | 2,506 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |